| Autor: |
Mollenhauer, Brit, Trenkwalder, Claudia, von Ahsen, Nicolas, Bibl, Mirko, Steinacker, Petra, Brechlin, Peter, Schindehuette, Jan, Poser, Sigrid, Wiltfang, Jens, Otto, Markus |
| Předmět: |
|
| Zdroj: |
Dementia & Geriatric Cognitive Disorders; 2006, Vol. 22 Issue 3, p200-208, 9p, 1 Diagram, 3 Charts |
| Abstrakt: |
Measurement of τ-protein and β-amyloid1–42 (Aβ42) in cerebrospinal fluid (CSF) has gained increasing acceptance in the differential diagnosis of Alzheimer’s disease. We investigated CSF τ-protein and Aβ42 concentrations in 73 patients with advanced idiopathic Parkinson’s disease with dementia (PDD) and 23 patients with idiopathic Parkinson’s disease without dementia (PD) and in a comparison group of 41 non-demented neurological patients (CG) using commercially available enzyme-linked-immunoabsorbant-assay (ELISA). τ-Protein levels were statistically significantly higher and Aβ42 lower in the PDD patients compared to PD patients and the CG. This observation was most marked (p < 0.05) in a subgroup of patients with PDD carrying the apolipoprotein genotype ε3/ε3. The distribution of the apolipoprotein genotypes in PDD and PD patients was similar to that of the CG. Although a significant difference in τ-protein values was observed between PDD and CG, no diagnostic cut-off value was established. These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
